Immune cell engineering for cancer therapy 2026
- Submission status
- Open
- Submission deadline
This Collection provides updated research from the Immune cell engineering for cancer therapy 2024 Collection.
Chimeric antigen receptor (CAR) T cell therapies have revolutionized the treatment of haematological malignancies; however, their application in solid tumors remains challenging. CAR technology has now extended beyond T-cells and applied to other immune cells, including NK cells and macrophages. Alternative immune-engineering approaches, including direct in vivo immune cell engineering, are also emerging. A tumor infiltrating lymphocyte (TIL)-based therapy has recently received FDA approval as the first cellular therapy for solid tumors.
With this Collection, a partnership between Nature Communications, Communications Medicine, Communications Biology, and Scientific Reports, we welcome submissions of primary research papers that focus on immune cell engineering for cancer therapy. The journals are particularly interested in preclinical studies proposing new engineering strategies and therapeutic developments.
Nature Communications, Communications Medicine, and Scientific Reports are also interested in publishing high-quality clinical research in the field.
We will highlight relevant papers in this Collection; unfortunately, we cannot guarantee that any individual paper will be included in the Collection.
This Collection is open for submissions from all authors – and not by invitation only – on the condition that the manuscripts fall within the scope of the Collection and the participating journals more generally.
All manuscripts will be considered for publication according to the editorial policies of the specific participating journal through which they are submitted. Visit Nature portfolio’s Collections guidelines for more details.
When submitting your manuscript to a participating journal via our online submission system, please choose the appropriate Collection title from the drop-down menu on the submission form. Please be sure to express your interest in the Collection in your cover letter. Please only submit to one journal, but note authors have the option to transfer to another participating journal following the editors’ recommendation.
This Collection has not been supported by sponsorship.
